Citations

Clear

1792 citation(s) found for "Stephanie".

Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia
Fink, Stephanie, Jenkins, Robert B. , Paternoster, Sarah F., Smoley, Stephanie A., Stockero, Kimberly J., Nast, Danielle M., Flynn, Heather C., Tschumper, Renee C. , Geyer, Susan M. , Call, Tim G., Jelinek, Diane F., Dewald, Gordon W., Shanafelt, Tait D. , Witzig, Thomas E. , Zent, Clive S. , Call, Timothy G., Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | September 28, 2006 | Volume: 24 | Issue: 28 | Pages: 4634-4641

10.1200/jco.2006.06.9492 | PMID 17008705 Get It

Purpose Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease. There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH. Patients and Methods Between 1994 and 2002, we enrolled 159 patients with previously untreated CLL (83% Rai stage 0/I) on a prospective trial evaluating clonal evolution by FISH. Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years. Results Chromosomal abnormalities detected by FISH at study entry predicted overall survival. Eighteen patients experienced clonal evolution during follow-up. The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years (n = 71; 1.4%) but 17 occurrences (n = 63; 27%) among patients tested after 5+ years. Clonal evolution occurred among 10% of ZAP-70–negative and 42% of ZAP-70–positive patients at 5+ years (P = .008). Conclusion This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease. Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution. These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL.
Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response
Cormier, Stephania A. , Taranova, Anna G. , Bedient, Carrie E., Protheroe, Cheryl, Pero, Ralph, Dimina, Dawn, Ochkur, Sergei I. , O'Neill, K.R. , Colbert, Dana, Lombari, Theresa R, Constant, Stephanie L., McGarry, Michael P. , Lee, James J. , Lee, Nancy A., Nguyen, Thanh D.

Mayo Clinic

Journal of Leukocyte Biology | April 14, 2006 | Volume: 79 | Issue: 6 | Pages: 1131-1139

10.1189/jlb.0106027 | PMID 16617160 Get It

Abstract Tumor-associated eosinophilia has been observed in numerous human cancers and several tumor models in animals; however, the details surrounding this eosinophilia remain largely undefined and anecdotal. We used a B16-F10 melanoma cell injection model to demonstrate that eosinophil infiltration of tumors occurred from the earliest palpable stages with significant accumulations only in the necrotic and capsule regions. Furthermore, the presence of diffuse extracellular matrix staining for eosinophil major basic protein was restricted to the necrotic areas of tumors, indicating that eosinophil degranulation was limited to this region. Antibody-mediated depletion of CD4+ T cells and adoptive transfer of eosinophils suggested, respectively, that the accumulation of eosinophils is not associated with T helper cell type 2-dependent immune responses and that recruitment is a dynamic, ongoing process, occurring throughout tumor growth. Ex vivo migration studies have identified what appears to be a novel chemotactic factor(s) released by stressed/dying melanoma cells, suggesting that the accumulation of eosinophils in tumors occurs, in part, through a unique mechanism dependent on a signal(s) released from areas of necrosis. Collectively, these studies demonstrate that the infiltration of tumors by eosinophils is an early and persistent response that is spatial-restricted. It is more important that these data also show that the mechanism(s) that elicit this host response occur, independent of immune surveillance, suggesting that eosinophils are part of an early inflammatory reaction at the site of tumorigenesis.
Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival
Sengupta, Shomik , Blute, Michael L., Bagniewski, Stephanie M., Myers, Robert P., Bergstralh, Eric J., Leibovich, Bradley C. , Zincke, Horst

Mayo Clinic

Journal of Urology | April 6, 2006 | Volume: 175 | Issue: 5 | Pages: 1684-1690

10.1016/s0022-5347(05)00978-x | PMID 16600730 Get It

Dietary Carotenoids and Risk of Lung Cancer in a Pooled Analysis of Seven Cohort Studies
Männistö, Satu , Smith‐Warner, Stephanie A. , Anderson, Kristin E. , Brandt, Piet A. van den , Cerhan, James R. , Colditz, Graham A. , Feskanich, Diane , Freudenheim, Jo L. , Giovannucci, Edward L. , Goldbohm, R. Alexandra, Graham, Saxon, Miller, Anthony B. , Rohan, Thomas E. , Virtamo, Jarmo, Spiegelman, Donna , Albanes, Demetrius , Willett, Walter C. , Hunter, David J. , Cerhan, James R , Colditz, Graham A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 22, 2006 | Volume: 13 | Issue: 1 | Pages: 40-48

10.1158/1055-9965.epi-038-3 | PMID 14744731 Get It

Abstract Intervention trials with supplemental β-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7–16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. β-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87–1.11; highest versus lowest quintile). The RRs for α-carotene, lutein/zeaxanthin, and lycopene were also close to unity. β-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67–0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in β-cryptoxanthin, such as citrus fruit, may modestly lower the risk.
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
Rae, James M. , Safgren, Stephanie L. , Ames, Matthew M. , Visscher, Daniel W., Reynolds, Carol, Lingle, Wilma L., Flockhart, David A., Desta, Zeruesenay , Perez, Edith A. , Goetz, Matthew P. , Suman, Vera J. , Couch, Fergus J. , Ingle, James N. , Safgren, Stephanie L

Mayo Clinic

Journal of Clinical Oncology | December 17, 2005 | Volume: 23 | Issue: 36 | Pages: 9312-9318

10.1200/jco.2005.03.3266 | PMID 16361630 Get It

Purpose Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown. Methods We determined cytochrome P450 (CYP)2D6 (*4 and *6) and CYP3A5 (*3) genotype from paraffin-embedded tumor samples and buccal cells (living patients) in tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial. The relationship between genotype and disease outcome was determined using the log-rank test and Cox proportional hazards modeling. Results Paraffin blocks were obtained from 223 of 256 eligible patients, and buccal cells were obtained from 17 living women. CYP2D6 (*4 and *6) and CYP3A5 (*3) genotypes were determined from 190, 194, and 205 patient samples and in 17 living women. The concordance rate between buccal and tumor genotype was 100%. Women with the CYP2D6 *4/*4 genotype had worse relapse-free time (RF-time; P = .023) and disease-free survival (DFS; P = .012), but not overall survival (P = .169) and did not experience moderate to severe hot flashes relative to women heterozygous or homozygous for the wild-type allele. In the multivariate analysis, women with the CYP2D6 *4/*4 genotype still tended to have worse RFS (hazard ratio [HR], 1.85; P = .176) and DFS (HR, 1.86; P = .089). The CYP3A5*3 variant was not associated with any of these clinical outcomes. Conclusion In tamoxifen-treated patients, women with the CYP2D6 *4/*4 genotype tend to have a higher risk of disease relapse and a lower incidence of hot flashes, which is consistent with our previous observation that CYP2D6 is responsible for the metabolic activation of tamoxifen to endoxifen.
An exploration of listener strategies in the lexical segmentation of hypokinetic dysarthric speech
Berger, Stephanie von, Caviness, John N., Edwards, Brian, Liss, Julie , Adler, Charles H.

Mayo Clinic

The Journal of the Acoustical Society of America | October 17, 2005 | Volume: 100 | Issue: 3 | Pages: 2573-2573

10.1121/1.417341 Get It

This investigation examined listener transcriptions of phrases produced by speakers with mild to severe hypokinetic dysarthria to examine individual strategies for the identification of word boundaries in connected speech. It was hypothesized that the most efficient listeners would use syllabic strength information to guide their parsing of the continuous acoustic stream. Six-hundred transcribed phrases (10 listeners ×60 phrases) were coded independently by two judges to identify (1) correct word transcriptions, (2) evidence of accurate lexical parsing, regardless of exact word identification, and (3) the proportions of accurate parsing of strong and weak syllable word onsets. Linear regression analysis of the group data revealed that correct segmentation of strong syllable word onsets predicted listener performance on segmenting weak syllable word onsets [R=0.805, F(1,29)=51.440, p<0.001]. Despite a wide range of listener performance on ``words correct,'' individual strategies for perceptual segmentation were evident only in the transcriptions for the most severe speaker. In this case, the poorest listeners exhibited disproportionate difficulty with the segmentation weak syllable word onsets. Results suggest that a listener's ability to use syllabic strength information in lexical parsing determines, in part, their ability to recognize word onsets. [Work supported by NIDCD, NIH.]
Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Kaufmann, Scott H. , Karp, Judith E. , Letendre, Louis, Kottke, Timothy, Safgren, Stephanie L. , Greer, Jackie , Gojo, Ivana , Atherton, Pamela J. , Svingen, Phyllis A., Loegering, David A., Litzow, Mark R. , Sloan, Jeff A. , Ames, Matthew M. , Adjei, Alex A. , Erlichman, Charles , Reid, Joel M. , Kaufmann, Scott H , Safgren, Stephanie L

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 18 | Pages: 6641-6649

10.1158/1078-0432.ccr-05-0817 | PMID 16166443 Get It

Abstract Purpose: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias. Experimental Design: Patients received topotecan and carboplatin by 5-day continuous infusion at nine dose levels. Patients achieving a complete remission received up to two additional courses for consolidation. Plasma topotecan and ultrafilterable platinum were assayed on days 1 to 5. In addition, pretreatment levels of various polypeptides in leukemic cells were examined by immunoblotting to assess possible correlations with response. Results: Fifty-one patients received a total of 69 courses of therapy. Dose-limiting toxicity consisted of grade 4/5 typhlitis and grade 3/4 mucositis after one course of therapy or grade 4 neutropenia and thrombocytopenia lasting >50 days when a second course was administered on day 21. Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete remission, and 1 reversion to chronic-phase chronic myelogenous leukemia. Topotecan steady-state plasma concentrations increased with dose. No accumulation of topotecan or ultrafilterable platinum occurred between days 1 and 5 of therapy. Leukemic cell levels of topoisomerase I, checkpoint kinase 1, checkpoint kinase 2, and Mcl-1 correlated with proliferating cell nuclear antigen but not with response. In contrast, low Bcl-2 expression correlated with response (P = 0.014, Mann-Whitney U test). Conclusions: The maximum tolerated dose was 1.6 mg/m2/d topotecan plus 150 mg/m2/d carboplatin. The complete remission rate in a heavily pretreated population was 16% (33% at the highest three dose levels). Responses seem to correlate with low pretreatment blast cell Bcl-2 expression.
Fruits and Vegetables and Ovarian Cancer Risk in a Pooled Analysis of 12 Cohort Studies
Koushik, Anita , Anderson, Kristin E. , Arslan, Alan A. , Brandt, Piet A. van den , Buring, Julie E. , Cerhan, James R. , Colditz, Graham A. , Fraser, Gary E. , Freudenheim, Jo L. , Goldbohm, R. Alexandra, Hankinson, Susan E. , Koenig, Karen L. , Larsson, Susanna C. , Leitzmann, Michael F. , McCullough, Marjorie L. , Miller, Anthony B. , Patel, Alpa V. , Rohan, Thomas E. , Schatzkin, Arthur, Smit, Ellen, Zhang, Shumin M., Smith‐Warner, Stephanie A. , Hunter, David J. , Spiegelman, Donna , Beeson, W. Lawrence , Genkinger, Jeanine M. , Hankinson, Susan E. , Willett, Walter C. , Wolk, Alicja , Cerhan, James R , Koushik, Anita , Arslan, Alan A , Colditz, Graham A , Larsson, Susanna C , McCullough, Marjorie L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 14 | Issue: 9 | Pages: 2160-2167

10.1158/1055-9965.epi-05-0218 | PMID 16172226 Get It

AbstractBecause fruits and vegetables are rich in bioactive compounds with potential cancer-preventive actions, increased consumption may reduce the risk of ovarian cancer. Evidence on the association between fruit and vegetable intake and ovarian cancer risk has not been consistent. We analyzed and pooled the primary data from 12 prospective studies in North America and Europe. Fruit and vegetable intake was measured at baseline in each study using a validated food-frequency questionnaire. To summarize the association between fruit and vegetable intake and ovarian cancer, study-specific relative risks (RR) were estimated using the Cox proportional hazards model, and then combined using a random-effects model. Among 560,441 women, 2,130 cases of invasive epithelial ovarian cancer occurred during a maximum follow-up of 7 to 22 years across studies. Total fruit intake was not associated with ovarian cancer risk—the pooled multivariate RR for the highest versus the lowest quartile of intake was 1.06 [95% confidence interval (95% CI), 0.92-1.21; P value, test for trend = 0.73; P value, test for between-studies heterogeneity = 0.74]. Similarly, results for total vegetable intake indicated no significant association (pooled multivariate RR, 0.90; 95% CI, 0.78-1.04, for the highest versus the lowest quartile; P value, test for trend = 0.06; P value, test for between-studies heterogeneity = 0.31). Intakes of botanically defined fruit and vegetable groups and individual fruits and vegetables were also not associated with ovarian cancer risk. Associations for total fruits and vegetables were similar for different histologic types. These results suggest that fruit and vegetable consumption in adulthood has no important association with the risk of ovarian cancer.
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Dewald, Gordon W., Therneau, Terry M. , Lee, You Kyoung , Fink, Stephanie, Smoley, Stephanie A., Paternoster, Sarah F., Adeyinka, Adewale, Ketterling, Rhett P. , Dyke, Daniel L. Van , Fonseca, Rafaël , Kyle, Robert A. , Larson, Dirk R. , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | July 20, 2005 | Volume: 106 | Issue: 10 | Pages: 3553-3558

10.1182/blood-2005-05-1981 | PMID 16030187 Get It

AbstractThe clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas inter-phase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17) (p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17) (p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.